Cancer Research Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 32, 637-642, March 1, 1972]
© 1972 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stöhrer, G.
Right arrow Articles by Brown, G. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stöhrer, G.
Right arrow Articles by Brown, G. B.

Enzymatic Activation of the Oncogen 3-Hydroxyxanthine1

Gerhard Stöhrer, Elaine Corbin and George Bosworth Brown

Division of Biological Chemistry, Sloan-Kettering Institute for Cancer Research, New York, New York 10021

The oncogen 3-hydroxyxanthine is enzymatically converted to a chemically reactive form by a protein fraction of the 100,000 x g supernatant of rat liver. The activated derivative reacts in vitro with free or protein-bound methionine, and the assay of the activation is based on the amount of 8-methylmercaptoxanthine formed; 3-hydroxyguanine yields 8-methylmercaptoguanine in this system. The cofactor requirements suggest that the activated intermediate is the 3-O-ester derived from 3-hydroxyxanthine and sulfuric acid. With cofactors favoring phosphate transfer, extensive activation is observed, but the participation of catalytic amounts of sulfate could not be excluded. Experiments with glucuronate or acetate transferring systems were inconclusive. 8-Methylmercaptoxanthine is not altered by the enzyme preparation, although the intact rat metabolized about 10% of it to a product which may be 8-methylsulfinylxanthine.

1 This investigation was supported in part by National Cancer Institute Grant CA 08748, and American Cancer Society Grant P-295. This is paper 42 of a series on "Purine N-Oxides." Portions were presented at the 61st Annual Meeting of the American Association for Cancer Research, Philadelphia, in April, 1970 (Proc. Am. Assoc. Cancer Res., 11: 76, 1970), and at the Tenth International Cancer Congress, Houston (Abstracts, 1970, p. 8).

Received 9/28/71. Accepted 12/ 9/71.




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
W. Lu and J. P. Uetrecht
Possible Bioactivation Pathways of Lamotrigine
Drug Metab. Dispos., July 1, 2007; 35(7): 1050 - 1056.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1972 by the American Association for Cancer Research.